Critical Decisions Driving Next-Generation Cell Line Development

Reliable cell lines are the backbone of therapeutic protein manufacturing, and new technologies like precision genome engineering and next-generation sequencing are changing the way these lines are optimized and characterized. In this Bioprocess Online Live, chief editor Tyler Menichiello was joined by Ted Peters, Ph.D., head of cell line development at Immunome, and Ronan O’Kennedy, Ph.D., from ROK Bioconsulting, to discuss cell line development (CLD) and characterization. The panel focused on how teams should approach critical decisions around platform selection, engineering, clonality, and CLD strategy, as well as the CMC documentation needed to meet regulatory requirements.